Literature DB >> 23904275

AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer.

Ana Paula Vidal1, Bruno M Andrade, Fernanda Vaisman, Juliana Cazarin, Luis Felipe Ribeiro Pinto, Marisa Maria Dreyer Breitenbach, Rossana Corbo, Adriana Caroli-Bottino, Fernando Soares, Mario Vaisman, Denise P Carvalho.   

Abstract

UNLABELLED: AMP-activated protein kinase (AMPK) is activated by the depletion in cellular energy levels and allows adaptive changes in cell metabolism and cell survival. Recently, our group described that AMPK plays an important role in the regulation of iodide and glucose uptake in thyroid cells. However, AMPK signaling pathway in human thyroid carcinomas has not been investigated so far.
OBJECTIVE: To evaluate the expression and activity of AMPK in papillary thyroid carcinomas.
METHODS: We examined total and phosphorylated AMPK (tAMPK and pAMPK) and phosphorylated acetyl-CoA-carboxylase (pACC) expressions through imunohistochemistry, using a tissue microarray block composed of 73 papillary thyroid carcinomas (PAP CA) or microcarcinomas (PAP MCA) and six adenoma (AD) samples from patients followed at the Federal University Hospital. The expression levels were compared with the non-neoplastic tissues from the same patient. Two different pathologists analyzed the samples and attributed scores of staining intensity and the proportion of stained cells. A total index was obtained by multiplying the values of intensity and the proportion of stained cells (INTxPROP).
RESULTS: tAMPK, pAMPK, and pACC showed a predominant cytoplasmic staining in papillary carcinomas, adenomas, and non-neoplastic thyroid tissues. However, the intensity and the proportion of stained cells were higher in carcinomas, so that a significant increase was found in the INTxPROP score both in PAP CA and PAP MCA, when compared with their respective controls.
CONCLUSION: Our results show unequivocally that AMPK pathway is highly activated in papillary thyroid carcinomas; however, more studies are necessary to understand the pathophysiological significance of AMPK activation in thyroid carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23904275     DOI: 10.1530/EJE-13-0284

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  16 in total

1.  Metformin effects on biochemical recurrence and metabolic signaling in the prostate.

Authors:  Brian Winters; Stephen Plymate; Steven B Zeliadt; Sarah Holt; Xiaotun Zhang; Elaine Hu; Daniel W Lin; Colm Morrissey; Bryan Wooldridge; John L Gore; Michael P Porter; Jonathan L Wright
Journal:  Prostate       Date:  2015-07-22       Impact factor: 4.104

Review 2.  Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.

Authors:  Giorgia Zadra; Julie L Batista; Massimo Loda
Journal:  Mol Cancer Res       Date:  2015-05-08       Impact factor: 5.852

Review 3.  Perspectives of the AMP-activated kinase (AMPK) signalling pathway in thyroid cancer.

Authors:  Bruno Moulin Andrade; Denise Pires de Carvalho
Journal:  Biosci Rep       Date:  2014-04-01       Impact factor: 3.840

4.  Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy.

Authors:  Yimin Zhang; Sarah J Storr; Kerstie Johnson; Andrew R Green; Emad A Rakha; Ian O Ellis; David A L Morgan; Stewart G Martin
Journal:  Oncotarget       Date:  2014-12-30

5.  No evidence for a decreased risk of thyroid cancer in association with use of metformin or other antidiabetic drugs: a case-control study.

Authors:  Claudia Becker; Susan S Jick; Christoph R Meier; Michael Bodmer
Journal:  BMC Cancer       Date:  2015-10-16       Impact factor: 4.430

Review 6.  Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.

Authors:  Shan Jin; Oyungerel Borkhuu; Wuyuntu Bao; Yun-Tian Yang
Journal:  J Clin Med Res       Date:  2016-02-27

Review 7.  Metabolic Reprogramming in Thyroid Carcinoma.

Authors:  Raquel Guimaraes Coelho; Rodrigo S Fortunato; Denise P Carvalho
Journal:  Front Oncol       Date:  2018-03-23       Impact factor: 6.244

8.  Identification and bioinformatics analysis of overlapping differentially expressed genes in depression, papillary thyroid cancer and uterine fibroids.

Authors:  Hanxiao Tang; Yongsheng Zhang
Journal:  Exp Ther Med       Date:  2018-04-02       Impact factor: 2.447

9.  mir-101-3p is a key regulator of tumor metabolism in triple negative breast cancer targeting AMPK.

Authors:  Peng Liu; Feng Ye; Xinhua Xie; Xing Li; Hailin Tang; Shuaijie Li; Xiaojia Huang; Cailu Song; Weidong Wei; Xiaoming Xie
Journal:  Oncotarget       Date:  2016-06-07

10.  Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in BRAFV600E Papillary Thyroid Carcinoma.

Authors:  Veronica Valvo; Asumi Iesato; Taylor R Kavanagh; Carmen Priolo; Zsuzsanna Zsengeller; Alfredo Pontecorvi; Isaac E Stillman; Suzanne D Burke; Xiaowen Liu; Carmelo Nucera
Journal:  Thyroid       Date:  2021-03-03       Impact factor: 6.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.